We have studied the role of cyclins and cyclin-dependent kinase (CDK) activity in apoptosis induced by camptothecin (CPT). In this model, 22% of the cells stain for annexin-V at 24 h and then proceed to be 93% positive by 72 h. This time window permits the analysis of cyclins in cells that are committed to apoptosis but not yet dead. We provide evidence that cyclin protein levels and then associated kinase levels increase after CPT treatment. Strikingly, cyclin B1 and cyclin E1 proteins are present at the same time in CPT treated HT29 cells. Although cyclin B1 and E1 CDK complexes are activated in CPT treated cells, only the cyclin B1 complex is required for apoptosis since reduction of cyclin B1 by RNAi or roscovitine treatment reduces the number of annexin-V-stained cells. We have detected poorly organized chromosomes and phosphorylated histone H3 epitopes at the time of maximum cyclin B1/CDK kinase activity in CPT-treated cells, which suggests that these cells enter a mitotic catastrophe. Understanding which CDKs are required for apoptosis may allow us to better adapt CDK inhibitors for use as anti-cancer compounds.
Introduction
Apoptosis and the cell division cycle are two cellular processes that are essential for normal development of metazoans. In an individual, however, if either of these processes is not regulated properly, the cell number can increase inappropriately to cause tumour formation (Hartwell and Kastan, 1994) . During apoptosis, cells die by following an ordered intracellular mechanism in which proteins and DNA are degraded. During the cell cycle, DNA is precisely duplicated rather than degraded and proteins are synthesized and degraded to assure progression through each phase of the cycle. Despite this fundamental difference between apoptosis and the cell cycle, there are increasing amounts of evidence that at some point these two processes use a common biochemical pathway and yet achieve a different result. Identifying and understanding this apoptotic pathway will be important in characterizing compounds for treating cancer.
The role of cyclin-dependent kinase (CDKs) in the cell cycle is well understood and different phases of the cell cycle can be characterized by the presence and the activity of different CDKs and cyclins. Somewhat surprisingly, CDK activity has also been described in cells undergoing apoptosis (Shi et al., 1994) ; for reviews see (Guo and Hay, 1999; Borgne and Golsteyn, 2003) . In contrast to the cell cycle, it is not known under which conditions CDKs function during apoptosis. This is the subject of the study described here.
A role for CDKs in apoptosis has been identified in different cell types by using many different experimental approaches. Apoptosis can be blocked in certain models of cultured human and murine cell lines by chemical inhibitors of CDKs, such as roscovitine (De Luca et al., 1997; Choi et al., 1999; Hsu et al., 1999) and structurally related purine type compounds such as olomoucine (Hsu et al., 1999) and purvalanol (Adachi et al., 2001) or a flavonoid compound, flavopiridol (Park et al., 1996) . Despite their chemical diversity, these small molecules bind to the ATP-binding pocket of the catalytic domain and reduce the activity of the enzyme (Vesely et al., 1994; Knockaert et al., 2002) . This suggests that CDK activity is required for apoptosis, as it is for the cell cycle. The effects of small molecule inhibitors can be mimicked by naturally occurring small inhibitor proteins, such as p21 cip1 , p27 kip1 , and p16 ink4 , which can inhibit the activity of CDK2 (Coqueret, 2003) and block apoptosis in HeLa cells (Harvey et al., 1998) , in fibroblasts (Hiromura et al., 1999) and in differentiating myocytes (Wang and Walsh, 1996) . Additional supportive experimental evidence for the role of CDK activity in apoptosis comes from studies that use 'kinase dead' mutants of CDK1 or CDK2 (Meikrantz and Schlegel, 1996; Harvey et al., 2000; Castedo et al., 2002b) . Finally, the FT210 murine cell line, which harbours a temperature sensitive mutation in the CDK1 gene, will not enter apoptosis when cultivated at the restrictive temperature and treated with apoptosisinducing agents (Shi et al., 1994) . Thus, inhibition of CDK activity by methods using chemical inhibitors, protein inhibitors and dominant negative genetics show that CDKs participate in apoptosis.
Although CDK inhibitors can protect cells from apoptosis, under certain conditions they can also induce apoptosis (Knockaert et al., 2002) . This property has lead to the development of inhibitors that are candidates for evaluation in preclinical and clinical studies. The biological mechanism of action of these compounds is not precisely known, however, it has been proposed that inhibition of distant Cdk1 family members such as Cdk7 and Cdk9 may lead to apoptosis (MacCallum et al., 2005) . Further research is required to uncover the specific role of each Cdk complex in apoptosis.
In cells undergoing apoptosis, the assignment of a cyclin to any specific event has not yet been made, although, many different examples of cyclin expression have been described. Cyclin E protein induction has been identified in IM-9, MOLT-4 and RPMI 8226 cell lines undergoing apoptosis (Mazumder et al., 2000) , neuronally derived cells (Padmanabhan et al., 1999) , as well as in HT29 cells treated with a novel acronycine derivative (Le´once et al., 2001) . B-type cyclins associated with CDK1 have been identified in HL60 cells as they enter apoptosis after treatment with the topoisomerase I inhibitor camptothecin (CPT) (Shimizu et al., 1995) and in epithelial-derived cell lines (Scatena et al., 1998) , a HeLa syncytia model (Castedo et al., 2002b) as well as neuronal cells (Shirvan et al., 1998) suggesting that this activity might be required for apoptosis in many different cell types (for review see Castedo et al. (2002a) ). In a similar manner, reports have also described that cyclin A protein levels and kinase activity increase during apoptosis (Meikrantz et al., 1994; Shi et al., 1996; Harvey et al., 1998; Hakem et al., 1999) .
A role of individual cyclins in apoptosis needs to be defined as has been done for cyclins during the cell cycle in order to understand how CDKs regulate apoptosis. This task is not simple because studies of cyclins in cells engaged in apoptosis are confounded by a background of cyclin function in the phase of the cell cycle during which apoptosis is occurring. We present an experimental model of HT29 cells engaged to enter apoptosis in which we analyse cyclin B1 and cyclin E1 kinase complexes. These kinase activities have been separated from their cell cycle phase-specific activity, and despite that the activity of both kinase complexes correlate well with apoptosis, we propose that only cyclin B1 is required for apoptosis in this experimental system.
Materials and methods

Cell lines
The human cell lines HT29 (colon adenocarcinoma) and HeLa were obtained from the American Type Culture Collection. HT29 cells were maintained in RPMI 1640 medium supplemented (RPMIc) with 10% decomplemented fetal calf serum (FCS), 2 mM L-glutamine (Invitrogen, Cergy-Pontoise, France), and 10 mM HEPES, pH 7.4. HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% decomplemented fetal calf serum, 2 mM L-glutamine, and 10 mM (N-2-hydroxyethlypiperazine-N 0 2 ethane sulphonic acid) (HEPES), pH 7.4.
Flow cytometric detection of apoptosis by annexin-V labelling, cell cycle phase and cyclins HT29 cells in exponential phase of growth were treated with CPT or not, the medium containing cells in suspension was collected and adherent cells were trypsinized. Cells were pooled and resuspended at a density of 10 6 cells/ml in culture medium containing 20% FCS. After 1 h incubation at 371C, cells were washed twice with cold PBS and resuspended in 500 ml of binding buffer (100 mM HEPES, pH 7.4, 14 mM NaCl, and 25 mM CaCl 2 ) containing 5 ml of annexin-V-fluorescein isothiocyanate (FITC) (Immunotech, Beckman, Marseille, France) and 10 mg/ml propidium iodide (PI) for 15 min at 41C in the dark. For each sample, approximately 10 5 cells were analysed by flow cytometry. FITC and PI emissions were collected through 520 and 630-nm bandpass filters, respectively.
For PI labelling, cells were fixed with ethanol and incubated for 30 min at room temperature in 1 ml PBS containing 100 mg/ ml RNase and 50 mg/ml PI (Sigma, Saint Quentin Fallavier, France). Cells were analysed on an Epics XL/MCL flow cytometer (Beckman Coulter, Cergy-Pontoise, France). To analyse cyclin proteins, samples were fixed with ethanol and washed twice with PBS, and incubated for 5 min in PBS containing 0.5% Triton X-100 at 41C. After two washes with PBS, cells were incubated for 2 h at room temperature with 5 ml of monoclonal anti-cyclin E1 (HE12, BD Pharmingen, San Diego, CA, USA), or 20 ml of FITC-conjugated monoclonal anti-cyclin B1 (GNS1, BD Pharmingen). Cyclin E1 was detected by incubation for 1 h with 20 ml of FITC-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Le Perrayen Yvelines, France).
Immunofluorescence analysis 2.5 Â 10 5 cells were cultured for 24 h before treatment with 1 mM CPT for various times. After one wash with PBS, cells were fixed in 3% formaldehyde for 20 min at room temperature and permeabilized for 5 min in 0.2% Triton X-100. Cells were incubated with polyclonal anti-cyclin B1 (H-433, Santa Cruz Biotechnology, 1:50) and/or monoclonal anti-cyclin E1 (13A3, Novocastra, Le Perrayen Yvelines, France, 1:80) or antiphospho-histone H3 (6G3, Cell Signalling, Saint Quentin, France, 1:50) for 2 h at room temperature. After three washes with PBS, Texas Red anti-rabbit (for cyclin B1), Texas Red anti-mouse (for phospho-histone H3) or FITC anti-mouse (for cyclin E1) secondary antibodies were added for 2 h. Nuclei were marked with DAPI. Cells were observed on a Zeiss Axioplan 2 microscope driven by Axiovision 3.1 software in which the linear range of the Zeiss HR camera was set first with non-treated cells. The number of cells that stained positive for cyclin B1, cyclin E1 or phospho-histone H3 was determined from photographs. A total of 200 cells were counted and the percent positive was calculated. The experiments were performed twice. Images were prepared with Photoshop 7.0 software without changing the linear dynamic range. Confocal images were collected on a Zeiss LSM 510 microscope within the linear dynamic range, free from signal crossover by separate excitation with either an Argon 488 laser or an HeNe 543 laser. DAPI signals were collected by excitation with a 405 nM diode source.
Measure of cyclin mRNA levels by real-time reverse transcriptase-polymerase chain reaction RNA (1 mg) from cells treated or not with CPT were subjected to a reverse transcription step using the cDNA archive Kit (Applied Biosystems, USA). Single-stranded cDNA products were then analysed by an ABI PRISM 7900HT Sequence Detection System using Cyclin B1 (Hs00259126_m1), Cyclin D1 (Hs00277039_m1), Cyclin E1 (Hs00233356_m1) and 18S rRNA (Hs99999901_s) mRNAs. In each case, triplicate threshold cycle (C t ) values were obtained and averaged; then expression levels were evaluated by the 2 ÀDDCt method (Livak and Schmittgen, 2001) . The fold change in cyclin B1, D1 or E1 was normalized to the 18S rRNA and compared to the untreated control (calibrator sample), using the following formula: ¼ 2 ÀDDCt ; where DDC t ¼ (C tÀtarget ÀC tÀreference ) treatedÀsample À(C tÀtarget À C tÀreference ) calibratorÀsample . Calibrator-sample represents the expression level (1 Â ) of the target gene normalized to 18S rRNA.
Cyclin immunoprecipitation
Cells (10 7 ) were resuspended in 1 ml extraction of buffer (25 mM Tris-HCl, pH 7.5, 25 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, protease inhibitors cocktail). After a 40 s sonication at 41C, the suspension was centrifuged at 12 000 g for 10 min at 41C. Extracts were either analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) or used for isolation of CDK/cyclin complexes by immunoprecipitation. Total cell lysate (0.5-1.0 mg) was incubated with antibodies directed against cyclin E1 (13A3, Novocastra, 8 ml), cyclin A2 (H-432, Santa Cruz, 5 ml) or cyclin B1 (GNS1, Santa Cruz, 5 ml) at 41C and complexes were recovered with protein A/G-sepharose beads. The beads were washed three times with bead buffer and twice with Buffer C (60 mM b-glycerophosphate, 15 mM p-nitrophenylphosphate, 25 mM MOPS (pH 7.2), 5 mM EGTA, 15 mM MgCl 2 , 1 mM DTT, 1 mM sodium vanadate, 1 mM phenylphosphate) (Meijer et al., 1989) .
Histone H1 kinase assay
The CDK complex beads were incubated in a reaction buffer containing 0.2 mg/ml histone H1 (Calbiochem, Fontenay-sousBois, France), 15 mM ATP, 0.2 mCi [g-33 P]ATP (Amersham GE, Saday, France) in Buffer C for 20 min at 301C. The reaction was stopped by addition of 20 ml 2 Â Laemmli sample buffer. Samples (20 ml) were loaded on gels. Signals were captured by an Amersham PhosphorImager Typhoon 9200 and analysed by ImageQuant 5.2 software (Molecular Dynamics, Amersham GE, Saday, France). Kinase activities are given in arbitrary units.
Electrophoresis and Western blotting
After standard PAGE and transfers, membranes were incubated with the primary antibody in milk as follows: polyclonal anti-cyclin A2 (H-432, Santa Cruz, 1:1000), monoclonal anti-cyclin B1 (GNS1, Santa Cruz, 1:500), monoclonal anti-cyclin E1 (HE12, BD Pharmingen, 1:500). The membranes were treated with horseradish peroxidase-coupled anti-mouse IgG (Amersham, 1:2000) for ECL detection.
Preparation and transfection of small interference RNA Double-stranded small interference RNA (siRNA) corresponding to the cDNA sequences of human cyclin E1 (AATGGCCAAAATCGACAGGAC, nucleotides 90-110), human cyclin B1 (AACAGCTCTTGGGGACATTGG, nucleotides 126-146) and human cyclin B1 with four mutations (AACAACTATTGGGAACGTTGG, nucleotides 126-146) were designed as recommended by (Elbashir et al., 2002) . The duplexes were purchased from Dharmacon Research Inc., Lafayette, CO, USA (for cyclin E1) and Proligo, Paris, France (for cyclin B1). A scrambled sequence (CAGTCGCGTTTGC GACTGG) was also included in control experiments (Dharmacon). Cells were cultured in six-well plastic plates in RPMIc medium and transfected by adding 12 ml of lipofectamine 2000 (Invitrogen) and siRNA in Optimem (500 ml final volume). The minimum active concentration for each siRNA duplex was determined emperically before use in experiments. Cells were rinsed 6 h post-transfection and maintained in culture for 24 h before addition of 1 mM CPT for additional 24 h before FACS and Western blot analysis.
Results
Characterisation of cell cycle profile and apoptosis in cells treated with CPT
We treated human colon carcinoma cells (HT29) with CPT in order to define experimental conditions that would permit the analysis of CDK activity in cells that are committed to apoptosis but not yet dead. Cells were incubated with various concentrations of CPT for 24 h and then analysed for annexin-V and PI labelling ( Figure 1a ). In comparison to other concentrations tested, 1 mM CPT gave the greatest number of cells positive for annexin-V labelling without PI staining (19%). These cells were considered to be in primary apoptosis. Treatments with higher or lower concentrations of CPT gave either fewer cells in primary apoptosis or a mixture of cells that stained for annexin-V and PI (secondary apoptosis). After 72 h of treatment, nearly 94% of the HT29 cells were positive for annexin-V labelling indicating that more than 70% of the nonapoptotic population at 24 h was indeed committed to apoptosis ( Figure 1b ).
Cells treated with 1 mM CPT were analysed by flow cytometry to determine their position in the cell cycle. The profile of treated cells at 24 h was similar to that of non-treated cells, revealing that the treated cells did not accumulate at a specific phase of the cell cycle ( Figure 1c ). Whereas lower concentrations of CPT lead to a G2-M-phase arrest ( (Shao et al., 1997) , not shown), this 'freezing' of the cell cycle was considered to be useful in that any changes in the expression of cyclins associated with cells committed to apoptosis would be independent of a classical cell cycle arrest.
We then examined cyclin A2, B1 and E1 protein levels by Western blotting of total cell extracts prepared from HT29 cells treated for various times with CPT ( Figure 2 ). Under these conditions, all cyclin protein levels increased, although the timing and the duration of the increase was different for each cyclin. Cyclin E1 protein levels increased as early as 8 h after treatment, whereas cyclin A2 and B1 levels showed a maximum level at 32 h. After 32 h cyclins A, B1 and E1 generally persisted throughout the duration of the experiment. The mRNA levels of cyclin D1, cyclin B1 and cyclin E1 were then analysed by quantitative PCR from total RNA isolated from cells treated with CPT for 24 h and these were compared with the levels of cyclin mRNAs in exponentially growing cells. Cyclin B1 mRNA levels increased 1.8-fold and cyclin E1 mRNA levels increased 2.7-fold after CPT treatment. By contrast, the level of cyclin D1 mRNA at 24 h CPT treatment was the same as that of untreated cells. The increase in cyclin B1 and E1 mRNA levels may, in part, contribute to the increase in protein levels. The increase in cyclin protein levels was independent of changes in the cell cycle phase, as shown in Figure 1c , although it was correlated with cells that were either dying or committed to apoptosis (Figure 1b) .
Cyclin B1 and cyclin E1 are expressed in the same cell at the same time during CPT-induced apoptosis We examined cyclin B1 and cyclin E1 proteins in HT29 cells by confocal microscopy and by FACS to determine which cells express increased levels of these proteins after CPT treatment. Strong cyclin E1 staining was detected in the nuclei of many cells (Figure 3 ). The merged image showed the striking simultaneous expression of cyclin B1 and cyclin E1 in the same cell. In addition, several different staining patterns could be detected, including cyclin B1 nuclear staining and cells that showed no cyclin B1 or cyclin E1 staining at all. At this timepoint, 15% of the cells counted co-expressed cyclin B1 and cyclin E1 (Figure 3b ), whereas coexpression was rarely detected in non-treated cells (image not shown). We then examined HeLa cells by confocal microscopy after treatment by CPT. We were able to detect the simultaneous expression of cyclin B1 and cyclin E1 proteins indicating that this unusual staining pattern was not limited to HT29 cells. The expression of cyclin B1 and E1 was also present in both cell types at 16 and at 32 h and rarely seen in non-treated cells (image not shown).
The expression of cyclin B1 and cyclin E1 within the same cell suggested that at least one of these two cyclins was likely expressed outside of its normal cell cycle phase. To examine this possibility, we analysed cells by flow cytometry at 4, 8 and 24 h after treatment with CPT to determine their position in the cell cycle relative to cyclin B1 and cyclin E1 protein expression (Figure 4) . In this experiment, in which 30% of the cells were positive for annexin-V labelling by 24 h CPT treatment (top row), cyclin E1 was strongly expressed in cells in G1/S-phase as expected, but also in G2/M-phase cells at 8 h and more strongly at 24 h at which time 35% of the cells expressed cyclin E1 outside of the G1 phase (middle row). Similarly, cyclin B1 was expressed in G2/M-phase cells as expected, but also in 36% of cells that were in the G1-phase of the cell cycle at 24 h after treatment (bottom row). These results complemented the observations made by confocal microscopy and show that under conditions that lead to apoptosis, cyclin B1 and cyclin E1 can be expressed outside of their classical cell cycle phase.
Cyclin A, B1 and E1 form active protein kinase complexes in CPT-treated cells The strong expression of both cyclins outside of their normal cell cycle phase led us to examine if cyclins were part of active CDK complexes or not. Cells were treated with CPT and then treated with the CDK inhibitor (R)-roscovitine (CYC202, Seliciclib) (Meijer et al., 1997) and analysed by flow cytometry for annexin-V labelling and PI labelling. Consistent with what had been reported in other models, roscovitine reduced the number of annexin-V staining cells from 47% in CPT treated cells to 28 and 12% (Figure 5a ). When tested separately, roscovitine did not induce apoptosis. The ability of a CDK inhibitor to reduce the number of annexin-V stained cells suggested that active CDK complexes were probably contributing the apoptotic programme in this model. We then tested the protein kinase activity associated with the cyclin complexes in cells treated with CPT at various times between 8 and 48 h after treatment. Cyclin A and cyclin B1 complexes showed a strong increase in associated kinase activity (Figure 5b and c) that appeared to be similar to increases in protein levels as detected by Western blotting (Figure 2) . By 32 h after treatment, relatively high levels of cyclin A and cyclin B1 kinase activity could be detected. Cyclin E1 complex activity levels were also measured and compared during treatment with CPT. The activity increased, as compared to non-treated cells, and remained active up to the last time point (Figure 5d ). These results suggested that three cyclin complexes tested are activated in CPT treated cells and support the interpretation that CDK activity is required in this apoptosis model. A role for cyclin B1 in apoptosis A Borgne et al
Reduction of cyclin B1 but not cyclin E1 reduces the number of cells that stain for annexin-V after treatment with CPT
To address directly the role of cyclin expression in the commitment to apoptosis, we wanted to reduce cyclin protein levels and then determine whether the kinetics of apoptosis entry were altered. We examined the levels of cyclin B1 in cells that were treated with roscovitine, or with roscovitine plus CPT. As shown in Figure 6a , cyclin B1 protein levels increased after CPT treatment. In the presence of roscovitine, however, cyclin B1 levels remained relatively low even after CPT treatment. The lack of cyclin B1 complex, as well as the inhibition of cyclin B1 activity may participate in the block of the apoptosis program as described Figure 4 . We explored this interpretation further by using RNA interference against cyclin B1 and measuring entry into apoptosis.
Cells were treated with siRNAs specific against human cyclin B1 and with control siRNAs containing a scrambled sequence. At 24 and 48 h after transfection, cells were analysed by FACS and by Western blotting to determine cyclin B1 protein levels (Figure 6b ). The cyclin B1 protein could not be detected in siRNA cyclin B1 treated cells at 48 h, even in cells that were co-treated with CPT, whereas a strong induction of cyclin B1 protein levels were detected in the control. Cells that did not express cyclin B1 protein were more likely to be in the G2/M phase of the cell cycle (38%) as compared to the control cells. By 48 h, there was a reduction in the number of cells in G2/M-phase (14%) and a corresponding increase in the number of cells with sub-G1 levels of DNA.
We then compared the effects of CPT upon primary apoptosis (annexin-V positive and PI negative) in cells that were negative for cyclin B1. At 24 h (Figure 6c ), cyclin B1 siRNA cells showed only 10% annexin-V positive cells whereas scrambled and transfected only cells showed 26 and 31% positive cells, respectively. By 48 h (Figure 6d ), only 39% of the cells were in primary apoptosis and 14% were in secondary apoptosis (53% total), whereas transfected only and scrambled cells showed 64 and 53% cells in primary apoptosis and 26 and 34% in secondary apoptosis (90 and 87% total) respectively. Cells in which the levels of cyclin B1 were lowered showed a consistent reduction in CPT-induced apoptosis.
Cyclin E1 protein levels and activity were also elevated in CPT-treated cells, therefore, we tested if it was required for apoptosis. As had been carried out for cyclin B1, cells were treated with siRNAs against human cyclin E1 and protein levels were analysed (Figure 7a ). The levels of cyclin E1 were strongly reduced in cells that were treated with siRNAs but not in cells that were treated with siRNAs against cyclin B1 or scrambled sequences. The absence of cyclin E1 had little effect upon the cell cycle profile (not shown). The number of siRNA cyclin E1 cells that stained for annexin-V either in primary or secondary apoptosis after CPT were similar to the control cells. This suggested that despite the strong induction of cyclin E1 protein and its associated protein kinase activity, this cyclin complex is not required for apoptosis in this model.
CPT-treated cells enter mitotic catastrophe at the time when cells have high cyclin B1 kinase activity
The requirement for cyclin B1 protein and activity in apoptosis led us to examine if these cells enter mitosis before dying. Cells were treated with CPT for varying times and then examined for mitotic figures (Figure 8a) . 
CPT 8h
Figure 4 CPT treated HT29 cells express cyclin B1 and cyclin E1 outside a standard cell cycle phase. HT29 cells were either not treated or treated with CPT for 4, 8 or 24 h and then analysed by flow cytometry for PI and annexin-V labelling (top row). In this experiment, 30% of the cells were in primary apoptosis and 6% in secondary apoptosis by 24 h treatment. A subset of these cells were then analysed to determine cyclin E1 or cyclin B1 protein expression relative to the cell cycle position. The intensity scale for cyclin E1 is logarithmic and the intensity scale for cyclin B1 is linear.
A role for cyclin B1 in apoptosis A Borgne et al
Cells that displayed chromosomes in either metaphase or anaphase configurations were easily detected with anti-phosphorylated histone H3 antibodies (top row) in control cells. Approximately 6% of cells in an exponentially growing culture can be detected by this method.
The number of cells that were positive for phosphohistone H3 staining were then counted at various times after CPT treatment (Figure 8b) . At 16 h o1% of the total cells were positive, whereas the number increased to 10% by 32 h, in a pattern that was similar to cyclin B1 kinase activity (Figure 5c ). At 32 and 40 h, chromosomes and DNA that co-stained with phospho-histone H3 appeared to be poorly organized as compared to the well-formed mitotic figures seen in control cells. The chromosomes shown in the enlarged images resembled that of chromosomes in cells in mitotic catastrophe. These results suggested that CPT-treated cells enter a mitotic catastrophe, and that this event was related to the requirement for cyclin B activity.
Discussion
We have developed an experimental model to study the potential role of cyclins in apoptosis. HT29 cells treated with CPT enter an apoptosis program in which progress through the cell cycle is blocked in all phases. By using this model we have obtained evidence that cyclin levels and activity increase during the period when cell engage the apoptosis program. Of these, cyclin B1 is partially required for the apoptosis program because the reduction of cyclin B1 protein by RNAi or by chemical inhibition decreases the number of apoptotic cells. To study the role of cyclins in apoptosis, it was necessary to identify chemical treatments that commit cells to apoptosis within a time scale amenable to further experimental manipulation. We chose to use the topoisomerase I inhibitor, CPT, at 1 mM by which 93% of HT 29 cells are in apoptosis in 72 h. At concentrations of around 100 nM, CPT induces a G2/M-phase block in the cell cycle by activating a DNA damage checkpoint ( (Tanizawa et al., 1994) , data not shown). Whereas these cells also enter apoptosis, it is more difficult to characterize a putative apoptosis-specific activity of cyclin B1/CDK1 complex in G2/M-phase cells because cyclin B1 protein levels are already elevated as compared to G1 cells where cyclin B1 levels are very low (Pines and Hunter, 1989) . Therefore, we used higher concentrations of CPT, as have been previously reported in the literature (Smits et al., 2000; Furuta et al., 2003) , at which cells were blocked in all major phases of the cell cycle. The reason for this cell cycle 'freezing' is not known but it provided a convenient experimental method that permitted us to observe the expression of cyclin E1 and cyclin B1 outside of their normal phase of the cell cycle.
We detected cyclin B1 protein expression both by flow cytometry and by immunofluorescence microscopy to confirm that the expression profile was not directly linked to the position of the cell in the cell cycle.
The expression of cyclin B1 outside of the G2/M-phase of the cell cycle has been previously reported in non-dividing neuronal cells, haematopoietic cell lines (Porter et al., 2000) and cells taken from human tumours (Shen et al., 2002) . The levels of cyclin B1 protein and associated activity decreased immediately after CPT treatment, as had been previously reported (Maity et al., 1996) . However, an increase in cyclin B1 kinase activity at approximately 32 h after treatment with CPT occurred when the majority of cells were not in the G2/M-phase as measured by DNA content.
Cells that express cyclin E1 outside of S-phase were detected by flow cytometry and the simultaneous expression of cyclin B1 and cyclin E1 in cells was also detected by confocal immunofluorescence microscopy. As in the case of cyclin B1, examples of cyclin E1 expression outside of the normal cell cycle phase have been reported in pluripotent murine embryonic cells (Stead et al., 2002) and in cells undergoing apoptosis (Mazumder et al., 2000) . The cyclin E1 complex was active at 16 h after treatment, which was earlier than cyclin A or cyclin B1 complexes. In contrast to previous reports, we did not detect small p18 forms of cyclin E that might induce activated CDK complexes (Porter et al., 2001; Mazumder et al., 2002) although the same antibody was used. A role for cyclin B1 in apoptosis A Borgne et al Several lines of evidence support the hypothesis that active CDK complexes participate in CPT-induced apoptosis. We found that cyclin A, B1 and E1 cyclin/ CDK complexes were active after treatment with CPT. Consistent with a role in apoptosis, (R)-roscovitine, which inhibits CDK1 and CDK2 catalytic subunits (Knockaert et al., 2002) also blocked the apoptotic program, although it does not permit one to identify which cyclin CDK complex is specifically required amongst the active complexes present. In addition to the known ATP competition activity of (R)-roscovitine, we found that cyclin B1 levels were reduced in the presence of this compound, even after CPT treatment.
A reduction in cyclin B1 protein levels after roscovitine and CPT treatment had been previously reported for synchronised HT29 cells (Abal et al., 2004) . The reduction is likely indirectly due to inhibition of CDK7/CDK9 complexes, whose activities are required for transcription of a variety of mRNAs including cyclin B1 and anti-apoptotic genes (MacCallum et al., 2005) . We then tested the role of cyclin B1 and cyclin E1 directly by blocking the expression by RNAi. siRNA for cyclin B1 reduced the amount of cyclin B1 protein and reduced the number of cells in primary apoptosis at 24 and 48 h. It has been previously reported that reduction of cyclin B1 protein by RNAi (without further treatment with cytotoxic agents such as CPT) increases the percentage of cells in G2/M-phase and initiates apoptosis by 48 h (Yuan et al., 2004) . In the results reported here, we also detected a cell cycle arrest and an increase in sub-G1 cells after siRNA treatment at 48 h ( Figure 6b ). The induction of a cell death pathway, independent of CPT, might explain why cyclin B1 siRNAs could not completely protect cells from CPT dependent apoptosis. Our results suggest that cyclin B1 has an important role in CPT dependent apoptosis and that there is a requirement for specific cyclin B1-dependent kinase activity rather than a generic CDK activity as might be supplied by active cyclin E complexes. Although the expression and corresponding activity of cyclin E1 correlated well with the induction of the apoptosis program, we were unable to reduce the number of cells in apoptosis with cyclin E1 siRNA. The reduction of cyclin E1 protein by RNAi is toxic to some cell lines after 96 h of culture (Li et al., 2003 ). In the model described here, we focused on activities within 48 h, at times when cyclin E levels were reduced. The expression of cyclin E1 might be related to other cellular processes such as stalled replication forks or an S-phase checkpoint (Bartek and Lukas, 2001 ). However, these activities would not be detected in tests designed to identify progression through apoptosis. Cyclin A protein levels also increased after CPT treatment (see Figure 2 ). The role of cyclin A is more difficult to evaluate because its level increases during both S-phase and during G2/M-phase of the cell cycle; we decided to focus our studies upon cyclin E1 and cyclin B1 because their expression is temporally distinct under proliferation conditions. The question of whether or not cells pass via a 'failed mitosis' or mitotic catastrophe during apoptosis has been prompted by the discovery of active CDK complexes during apoptosis (Fotedar et al., 1995; Castedo et al., 2002a) . A link between entry into mitosis and apoptosis has been described in a different model in which HeLa Env/CD4 syncytia express active cyclin B/CDK1 complexes. In these cells, the nuclear lamina disappears, microtubules are reorganised into multipolar spindles and DNA condenses into chromosome like structures, which is reminiscent of a mitotic catastrophe (Castedo et al., 2002b) . Mitotic catastrophe has also been identified in HT29 cells treated with C-1311, a putative topoisomerase II inhibitor (Hyzy et al., 2005) . We directly observed CPT treated cells by confocal microscopy and detected cells with chromosomes that were poorly organized relative to non-treated cells (Figure 8 ). These cells also expressed phosphohistone H3, a phosphorylated epitope that is expressed during mitosis in proliferating cells (Sauve et al., 1999) . The coexpression of phospho-histone H3 in cells with condensed chromosomes, at the time when cyclin B1 is active, strongly supports the idea that these cells have entered a mitotic catastrophe.
The activation of a cyclin B1 complex and its eventual outcome on the cell might be determined by the cellular context. For example, the expression of cyclin B1 gene and production of protein outside of the G2/M-phase of the cell cycle may create a cellular context in which cyclin B1 can be used for apoptosis rather than cell division (Shen et al., 2004) . The localization of cyclin B1 has an important role in apoptosis in haemopoieticderived cells (Porter et al., 2003) . There also may be a different accessibility to substrates of cyclin B/CDK1 that would change the outcome of its activity. For example, the pro-apoptotic protein BAD is phosphorylated by cyclin B1/CDK1 both in vitro and in vivo during apoptosis in postmitotic neurons (Konishi et al., 2002) . We were unable to detect Bad phosphorylation in our model. In view of the increasing amount of evidence that CDK1 (and other CDKs) participate in apoptosis, it is possible that CDKs are activated and function in a controlled manner during apoptosis rather than their misregulation or 'unscheduled' activity being the cause of apoptosis. With this view in mind, we have characterized the CPT-induced apoptosis model because relatively long period before cell death will permit detailed analysis of CDK complexes in apoptosis.
An important difference between cyclin B1 in apoptosis and cyclin B1 in mitosis is that cyclin B1/CDK1 is required for progression into the cell cycle in all species, whereas there are examples in which apoptosis functions without active cyclin B1, or more for review rarely, without a CDK complex (Castedo et al., 2002a ; for review Borgne and Golsteyn, 2003;  (Knockaert et al., 2002) . In addition, CDK inhibitors could be used to protect cells from the undesired effects of classical chemotherapeutic agents, as illustrated by the protective effects of roscovitine upon renal cells treated with cisplatin (Price et al., 2004) .
The multiple effects of CDK inhibitors upon various members of the CDK protein family may, in some instances, determine the anti-or proapoptotic outcome of certain inhibitors. For example, roscovitine may enhance the activity of CPT derivatives in vivo (Abal et al., 2004) , via its effects on transcription in addition to its effects upon CDK1 and CDK2 (MacCallum et al., 2005) .
In one case, there is a need to reduce the proliferative index of tumours, yet in another case, it is necessary to promote apoptosis of tumours cells. If CDKs have a role both in apoptosis as well as proliferation, it will be important to identify the apoptotic pathways in which CDKs function. This would permit a more rational use of CDK inhibitors as potential anti-tumour agents.
Abbreviations CDK, cyclin-dependent kinase; CPT, camptothecin; FCS, fetal calf serum; PI, propidium iodide.
